Skip to main content
Top
Published in: Current Atherosclerosis Reports 5/2011

01-10-2011

The SHAPE Guideline: Ahead of Its Time or Just in Time?

Authors: Erling Falk, Prediman K. Shah

Published in: Current Atherosclerosis Reports | Issue 5/2011

Login to get access

Abstract

In 2006, a grass roots movement called SHAPE (Screening for Heart Attack Prevention and Education) published a novel practice guideline for cardiovascular screening in the asymptomatic at-risk population. It suggested the use of noninvasive tests for subclinical atherosclerosis in cardiovascular risk assessment to target intensified preventive care to those at highest risk. The SHAPE guideline received much attention but not as much support from the “official” medical societies. However, subsequent studies published since 2006 have now provided strong supportive evidence for the strategy spearheaded by the SHAPE guideline. Indeed, the latest guidelines issued jointly by the American Heart Association and the American College of Cardiology have elevated recommendation levels for noninvasive imaging of subclinical atherosclerosis. This change is widely viewed as a significant step toward the SHAPE guidelines. The background for SHAPE and the evidence behind the recommendation to use coronary artery calcium score measured by computed tomography, carotid intima-media thickness and plaque measured by ultrasound, and ankle-brachial index in cardiovascular risk assessment is reviewed in this article.
Literature
1.
4.
go back to reference Schaar JA, Muller JE, Falk E, et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J. 2004;25:1077–82.PubMedCrossRef Schaar JA, Muller JE, Falk E, et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J. 2004;25:1077–82.PubMedCrossRef
5.
go back to reference Roger VL, Go AS, Lloyd-Jones DM, on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011;123:e18–209.PubMedCrossRef Roger VL, Go AS, Lloyd-Jones DM, on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011;123:e18–209.PubMedCrossRef
7.
go back to reference •• Dudas K, Lappas G, Stewart S, Rosengren A. Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006). Circulation. 2011;123:46–52. One of the most frightening aspects of coronary heart disease is sudden and unexpected death. Case fatality associated with a first coronary event is often underestimated when only those who survive to reach a hospital are considered. This high-quality study from Sweden found that the great majority of all fatal coronary events occur outside the hospital, and this proportion is increasing, particularly among younger individuals. PubMedCrossRef •• Dudas K, Lappas G, Stewart S, Rosengren A. Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006). Circulation. 2011;123:46–52. One of the most frightening aspects of coronary heart disease is sudden and unexpected death. Case fatality associated with a first coronary event is often underestimated when only those who survive to reach a hospital are considered. This high-quality study from Sweden found that the great majority of all fatal coronary events occur outside the hospital, and this proportion is increasing, particularly among younger individuals. PubMedCrossRef
8.
go back to reference Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664–72.PubMedCrossRef Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664–72.PubMedCrossRef
9.
go back to reference Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003;108:1772–8.PubMedCrossRef Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003;108:1772–8.PubMedCrossRef
10.
go back to reference Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, et al. From vulnerable plaque to vulnerable patient–Part III: Executive summary of the Screening for Heart Attack Prevention and Education Task Force report. Am J Cardiol. 2006;98:2H–15H.PubMedCrossRef Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, et al. From vulnerable plaque to vulnerable patient–Part III: Executive summary of the Screening for Heart Attack Prevention and Education Task Force report. Am J Cardiol. 2006;98:2H–15H.PubMedCrossRef
11.
go back to reference Yusuf S, Hawken S, Ounpuu S, INTERHEART Study Investigators, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.PubMedCrossRef Yusuf S, Hawken S, Ounpuu S, INTERHEART Study Investigators, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.PubMedCrossRef
12.
go back to reference •• Capewell S, O’Flaherty M. Rapid mortality falls after risk-factor changes in populations. Lancet. 2011 Mar 15. [Epub ahead of print]. This comment in The Lancet provides strong evidence for the optimistic view that coronary mortality can fall rapidly and dramatically with population-wide lifestyle changes. •• Capewell S, O’Flaherty M. Rapid mortality falls after risk-factor changes in populations. Lancet. 2011 Mar 15. [Epub ahead of print]. This comment in The Lancet provides strong evidence for the optimistic view that coronary mortality can fall rapidly and dramatically with population-wide lifestyle changes.
13.
go back to reference Wald NJ, Morris JK, Rish S. The efficacy of combining several risk factors as a screening test. J Med Screen. 2005;12:197–201.PubMedCrossRef Wald NJ, Morris JK, Rish S. The efficacy of combining several risk factors as a screening test. J Med Screen. 2005;12:197–201.PubMedCrossRef
14.
go back to reference Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419–24.PubMedCrossRef Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419–24.PubMedCrossRef
15.
16.
go back to reference Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377:1085–95.PubMed Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377:1085–95.PubMed
17.
go back to reference Lauer MS. Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk. JAMA. 2007;297:1376–8.PubMedCrossRef Lauer MS. Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk. JAMA. 2007;297:1376–8.PubMedCrossRef
18.
go back to reference Wilson PWF, Pencina M, Jacques P, et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2008;1:92–7.PubMedCrossRef Wilson PWF, Pencina M, Jacques P, et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2008;1:92–7.PubMedCrossRef
19.
go back to reference Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction. The Reynolds Risk Score for men. Circulation. 2008;118:2243–51.PubMedCrossRef Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction. The Reynolds Risk Score for men. Circulation. 2008;118:2243–51.PubMedCrossRef
20.
go back to reference Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611–9.PubMedCrossRef Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611–9.PubMedCrossRef
21.
go back to reference Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol. 2009;38:217–31.PubMedCrossRef Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol. 2009;38:217–31.PubMedCrossRef
22.
go back to reference • Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376:1393–400. A genetic risk score based on 13 recently discovered single nucleotide polymorphisms associated with coronary heart disease did not improve risk prediction substantially over traditional risk factors and family history. PubMedCrossRef • Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376:1393–400. A genetic risk score based on 13 recently discovered single nucleotide polymorphisms associated with coronary heart disease did not improve risk prediction substantially over traditional risk factors and family history. PubMedCrossRef
23.
go back to reference Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166–76.PubMedCrossRef Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166–76.PubMedCrossRef
24.
go back to reference •• Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56:e50-e103. This guideline describes the clinical use of coronary artery calcium score by computed tomography, intima-media thickness and plaque by carotid ultrasound, and ankle-brachial index in primary prevention of atherosclerotic cardiovascular disease. PubMedCrossRef •• Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56:e50-e103. This guideline describes the clinical use of coronary artery calcium score by computed tomography, intima-media thickness and plaque by carotid ultrasound, and ankle-brachial index in primary prevention of atherosclerotic cardiovascular disease. PubMedCrossRef
25.
go back to reference •• Shah PK. Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we? J Am Coll Cardiol 2010;56:98–105. This article provides strong evidence for the practical utility of selective screening for subclinical atherosclerosis in asymptomatic people at intermediate risk of cardiovascular disease. PubMedCrossRef •• Shah PK. Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we? J Am Coll Cardiol 2010;56:98–105. This article provides strong evidence for the practical utility of selective screening for subclinical atherosclerosis in asymptomatic people at intermediate risk of cardiovascular disease. PubMedCrossRef
26.
go back to reference Jacobson PD. Transforming clinical practice guidelines into legislative mandates: proceed with abundant caution. JAMA. 2008;299:208–10.PubMedCrossRef Jacobson PD. Transforming clinical practice guidelines into legislative mandates: proceed with abundant caution. JAMA. 2008;299:208–10.PubMedCrossRef
27.
28.
go back to reference Potential conflicts of interest can be found in the printed version of the SHAPE Guideline (Am J Cardiol. 2006, Suppl H). Potential conflicts of interest can be found in the printed version of the SHAPE Guideline (Am J Cardiol. 2006, Suppl H).
29.
go back to reference Kannel WB, D’Agostino RB, Sullivan L, Wilson PW. Concept and usefulness of cardiovascular risk profiles. Am Heart J. 2004;148:16–26.PubMedCrossRef Kannel WB, D’Agostino RB, Sullivan L, Wilson PW. Concept and usefulness of cardiovascular risk profiles. Am Heart J. 2004;148:16–26.PubMedCrossRef
30.
go back to reference Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults final report. Circulation. 2002;106:3143–3421. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults final report. Circulation. 2002;106:3143–3421.
31.
go back to reference Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.PubMedCrossRef Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.PubMedCrossRef
32.
go back to reference Schlendorf KH, Nasir K, Blumenthal RS. Limitations of the Framingham risk score are now much clearer. Prev Med. 2009;48:115–6.PubMedCrossRef Schlendorf KH, Nasir K, Blumenthal RS. Limitations of the Framingham risk score are now much clearer. Prev Med. 2009;48:115–6.PubMedCrossRef
33.
go back to reference Karim R, Hodis HN, Detrano R, Liu CR, Liu CH, Mack WJ. Relation of Framingham risk score to subclinical atherosclerosis evaluated across three arterial sites. Am J Cardiol. 2008;102:825–380.PubMedCrossRef Karim R, Hodis HN, Detrano R, Liu CR, Liu CH, Mack WJ. Relation of Framingham risk score to subclinical atherosclerosis evaluated across three arterial sites. Am J Cardiol. 2008;102:825–380.PubMedCrossRef
34.
go back to reference Nasir K, Michos ED, Blumenthal RS, Raggi P. Detection of high-risk young adults and women by coronary calcium and National Cholesterol Education Program Panel III guidelines. J Am Coll Cardiol. 2005;46:1931–6.PubMedCrossRef Nasir K, Michos ED, Blumenthal RS, Raggi P. Detection of high-risk young adults and women by coronary calcium and National Cholesterol Education Program Panel III guidelines. J Am Coll Cardiol. 2005;46:1931–6.PubMedCrossRef
35.
go back to reference Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol. 2003;41:1475–9.PubMedCrossRef Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol. 2003;41:1475–9.PubMedCrossRef
36.
go back to reference Sillesen H, Falk E. Why not screen for subclinical atherosclerosis? Lancet. 2011 Mar 25. [Epub ahead of print] Sillesen H, Falk E. Why not screen for subclinical atherosclerosis? Lancet. 2011 Mar 25. [Epub ahead of print]
37.
go back to reference Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo Jr JL, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761–88. Epub 2007 May 14. Erratum in: Circulation. 2007 Jul 31;116(5):e121.PubMedCrossRef Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo Jr JL, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761–88. Epub 2007 May 14. Erratum in: Circulation. 2007 Jul 31;116(5):e121.PubMedCrossRef
38.
go back to reference Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011 Apr 25. [Epub ahead of print] Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011 Apr 25. [Epub ahead of print]
39.
go back to reference • Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation. 2011;123:1243–62. Without discussing alternative options and consequences, these guidelines lower the threshold for high-risk down into the official low-risk category as defined by the National Cholesterol Education Program-ATP III guidelines. PubMedCrossRef • Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation. 2011;123:1243–62. Without discussing alternative options and consequences, these guidelines lower the threshold for high-risk down into the official low-risk category as defined by the National Cholesterol Education Program-ATP III guidelines. PubMedCrossRef
40.
go back to reference • Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. J Am Coll Cardiol 2010;56:1864–94. This article provides evidence for the clinical utility of cardiac computed tomography, including coronary artery calcium scoring in cardiovascular risk assessment. PubMedCrossRef • Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. J Am Coll Cardiol 2010;56:1864–94. This article provides evidence for the clinical utility of cardiac computed tomography, including coronary artery calcium scoring in cardiovascular risk assessment. PubMedCrossRef
41.
go back to reference Weissler AM. Traditional risk factors for coronary heart disease [letter]. JAMA. 2004;291:299–300.PubMedCrossRef Weissler AM. Traditional risk factors for coronary heart disease [letter]. JAMA. 2004;291:299–300.PubMedCrossRef
42.
go back to reference •• Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010;303:1610–6. This is a population-based study (Multi-Ethnic Study of Atherosclerosis) showing that coronary artery calcium scoring by computed tomography can be used to correctly reclassify a substantial number of healthy people at intermediate risk of cardiovascular disease. PubMedCrossRef •• Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010;303:1610–6. This is a population-based study (Multi-Ethnic Study of Atherosclerosis) showing that coronary artery calcium scoring by computed tomography can be used to correctly reclassify a substantial number of healthy people at intermediate risk of cardiovascular disease. PubMedCrossRef
43.
go back to reference •• Erbel R, Möhlenkamp S, Moebus S, et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol. 2010;56:1397–406. This is a population-based study confirming the MESA study described above by Polonsky et al. [42••]. PubMedCrossRef •• Erbel R, Möhlenkamp S, Moebus S, et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol. 2010;56:1397–406. This is a population-based study confirming the MESA study described above by Polonsky et al. [42••]. PubMedCrossRef
44.
go back to reference Greenland P, Bonow RO, Brundage BH, American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography); Society of Atherosclerosis Imaging and Prevention; Society of Cardiovascular Computed Tomography, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation. 2007;115:402–26.PubMedCrossRef Greenland P, Bonow RO, Brundage BH, American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography); Society of Atherosclerosis Imaging and Prevention; Society of Cardiovascular Computed Tomography, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation. 2007;115:402–26.PubMedCrossRef
45.
46.
go back to reference Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21:93–111.PubMedCrossRef Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21:93–111.PubMedCrossRef
47.
go back to reference •• Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. 2010;55:1600–7. This is a population-based study (Atherosclerosis Risk in Communities) showing that intima-media thickness and plaque by carotid ultrasound can be used to correctly reclassify a significant number of healthy people at intermediate risk of cardiovascular disease. PubMedCrossRef •• Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. 2010;55:1600–7. This is a population-based study (Atherosclerosis Risk in Communities) showing that intima-media thickness and plaque by carotid ultrasound can be used to correctly reclassify a significant number of healthy people at intermediate risk of cardiovascular disease. PubMedCrossRef
48.
go back to reference Polak JF, Pencina MJ, Pencina KM, O’Donnell CJ, Wolf PA, D’Agostino RB Sr. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med. 2011;365:213–21.PubMedCrossRef Polak JF, Pencina MJ, Pencina KM, O’Donnell CJ, Wolf PA, D’Agostino RB Sr. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med. 2011;365:213–21.PubMedCrossRef
49.
go back to reference Newman AB, Naydeck BL, Sutton-Tyrrell K, Edmundowicz D, O’Leary D, Kronmal R, et al. Relationship between coronary artery calcification and other measures of subclinical cardiovascular disease in older adults. Arterioscler Thromb Vasc Biol. 2002;22:1674–9.PubMedCrossRef Newman AB, Naydeck BL, Sutton-Tyrrell K, Edmundowicz D, O’Leary D, Kronmal R, et al. Relationship between coronary artery calcification and other measures of subclinical cardiovascular disease in older adults. Arterioscler Thromb Vasc Biol. 2002;22:1674–9.PubMedCrossRef
50.
go back to reference Folsom AR, Kronmal RA, Detrano RC, O’Leary DH, Bild DE, Bluemke DA, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med. 2008;168:1333–9.PubMedCrossRef Folsom AR, Kronmal RA, Detrano RC, O’Leary DH, Bild DE, Bluemke DA, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med. 2008;168:1333–9.PubMedCrossRef
51.
go back to reference Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197–208.PubMedCrossRef Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197–208.PubMedCrossRef
52.
go back to reference •• Criqui MH, McClelland RL, McDermott MM, Allison MA, Blumenthal RS, Aboyans V, et al. The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2010;56:1506–12. This is a population-based study (MESA) showing that both a low (<1.00) and a high (≥1.40) ABI identify people at increased risk of cardiovascular disease and can be used to improve risk classification beyond risk factor scoring. PubMedCrossRef •• Criqui MH, McClelland RL, McDermott MM, Allison MA, Blumenthal RS, Aboyans V, et al. The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2010;56:1506–12. This is a population-based study (MESA) showing that both a low (<1.00) and a high (≥1.40) ABI identify people at increased risk of cardiovascular disease and can be used to improve risk classification beyond risk factor scoring. PubMedCrossRef
53.
go back to reference Hecht HS. The deadly double standard (the saga of screening for subclinical atherosclerosis). Am J Cardiol. 2008;101:1805–7.PubMedCrossRef Hecht HS. The deadly double standard (the saga of screening for subclinical atherosclerosis). Am J Cardiol. 2008;101:1805–7.PubMedCrossRef
54.
go back to reference •• Rozanski A, Gransar H, Shaw LJ, Kim J, Miranda-Peats L, Wong ND, et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J Am Coll Cardiol. 2011;57:1622–32. This is a randomized trial showing that randomization to coronary artery calcium scanning (versus no scanning) was associated with superior risk factor control without increasing downstream medical testing. PubMedCrossRef •• Rozanski A, Gransar H, Shaw LJ, Kim J, Miranda-Peats L, Wong ND, et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J Am Coll Cardiol. 2011;57:1622–32. This is a randomized trial showing that randomization to coronary artery calcium scanning (versus no scanning) was associated with superior risk factor control without increasing downstream medical testing. PubMedCrossRef
55.
56.
go back to reference Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44.PubMedCrossRef Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44.PubMedCrossRef
57.
go back to reference Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011;124:146–53.PubMed Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011;124:146–53.PubMed
Metadata
Title
The SHAPE Guideline: Ahead of Its Time or Just in Time?
Authors
Erling Falk
Prediman K. Shah
Publication date
01-10-2011
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 5/2011
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-011-0195-y

Other articles of this Issue 5/2011

Current Atherosclerosis Reports 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine